Measures · D05 in 2022 · Part D · DD3 Member Experience with the Drug Plan
Rating of Drug Plan
Drug PlanMember ExperienceSource: CAHPS
- What it measures
- Percent of the best possible score the plan earned from members who rated the prescription drug plan.
- How it's calculated
- This case-mix adjusted measure is used to assess members' overall view of their prescription drug plan. The Consumer Assessment of Healthcare Providers and Systems (CAHPS) score uses the mean of the distribution of responses converted to a scale from 0 to 100. The score shown is the percentage of the best possible score each contract earned.
- Data source
- CAHPS CAHPS Survey Questions (question numbers vary depending on survey type): • Using any number from 0 to 10, where 0 is the worst prescription drug plan possible and 10 is the best prescription drug plan possible, what number would you use to rate your prescription drug plan?
- Measurement period
- 03/2021 – 05/2021
- Better when
- Higher
- Weight
- 2 (Patients’ Experience and Complaints Measure)
- Star assignment
- Relative Distribution and Significance Testing
- Case-mix adjusted
- Yes
- In improvement measure
- Yes
- Used in CAI
- No
- Notes
- CAHPS Survey results were sent to each contract's Medicare Compliance Officer in August 2021. These reports provide further explanation of the CAHPS scoring methodology and provide detailed information on why a specific rating was assigned.
- Disaster policy
- Higher measure star (2021-2022) for contracts with 25% or more enrolled affected by 2020 disasters.
From the 2022 Star Ratings Technical Notes (CMS).
Cut points over time
Score needed to earn each star level. Part D thresholds differ for MA-PD and standalone PDP contracts. Dotted lines and open dots: where the cut points may move for 2028.
How the 2028 cut points are projected
Each boundary moves by its median year-on-year change since 2019. It's the same projection the Star outlook uses for every contract. CMS sets real cut points from all contracts' scores each year, so treat these as a direction, not a forecast of the exact number.
| Stars | Org type | 2027 | Projected 2028 | Move |
|---|---|---|---|---|
| 2★ | MA-PD | 84 | 85 | +1 |
| 3★ | MA-PD | 86 | 86 | 0 |
| 4★ | MA-PD | 87 | 87 | 0 |
| 5★ | MA-PD | 89 | 89 | 0 |
| 2★ | PDP | 82 | 82 | 0 |
| 3★ | PDP | 83 | 83 | 0 |
| 4★ | PDP | 86 | 86 | 0 |
| 5★ | PDP | 88 | 88 | 0 |
2022 star distribution
Not rated: Plan too new to be measured (154); Plan too small to be measured (124); No data available (39); Plan not required to report measure (10); Not enough data available (4)
Cut point bands
| Star year | Org type | 1★ | 2★ | 3★ | 4★ | 5★ |
|---|---|---|---|---|---|---|
| 2027 | MA-PD | < 84 | >= 84 to < 86 | >= 86 to < 87 | >= 87 to < 89 | >= 89 |
| 2027 | PDP | < 82 | >= 82 to < 83 | >= 83 to < 86 | >= 86 to < 88 | >= 88 |
| 2026 | MA-PD | < 85 | >= 85 to < 86 | >= 86 to < 88 | >= 88 to < 89 | >= 89 |
| 2026 | PDP | < 82 | >= 82 to < 83 | >= 83 to < 86 | >= 86 to < 88 | >= 88 |
| 2025 | MA-PD | < 84 | >= 84 to < 86 | >= 86 to < 87 | >= 87 to < 89 | >= 89 |
| 2025 | PDP | < 79 | >= 79 to < 82 | >= 82 to < 85 | >= 85 to < 87 | >= 87 |
| 2024 | MA-PD | < 84 | >= 84 to < 85 | >= 85 to < 87 | >= 87 to < 89 | >= 89 |
| 2024 | PDP | < 80 | >= 80 to < 81 | >= 81 to < 83 | >= 83 to < 87 | >= 87 |
| 2023 | MA-PD | < 83 | >= 83 to < 85 | >= 85 to < 87 | >= 87 to < 88 | >= 88 |
| 2023 | PDP | < 79 | >= 79 to < 80 | >= 80 to < 83 | >= 83 to < 87 | >= 87 |
| 2022 | MA-PD | < 84 | >= 84 to < 85 | >= 85 to < 87 | >= 87 to < 88 | >= 88 |
| 2022 | PDP | < 80 | >= 80 to < 82 | >= 82 to < 84 | >= 84 to < 87 | >= 87 |
| 2021 | MA-PD | < 83 | >= 83 to < 84 | >= 84 to < 86 | >= 86 to < 87 | >= 87 |
| 2021 | PDP | < 80 | >= 80 to < 81 | >= 81 to < 83 | >= 83 to < 87 | >= 87 |
| 2020 | MA-PD | < 83 | ? 83 to < 84 | ? 84 to < 86 | ? 86 to < 87 | ? 87 |
| 2020 | PDP | < 80 | ? 80 to < 81 | ? 81 to < 83 | ? 83 to < 87 | ? 87 |
| 2019 | MA-PD | < 82 | ? 82 to < 83 | ? 83 to < 85 | ? 85 to < 87 | ? 87 |
| 2019 | PDP | < 80 | ? 80 to < 81 | ? 81 to < 84 | ? 84 to < 86 | ? 86 |
| 2018 | MA-PD | < 81 | ? 81 to < 83 | ? 83 to < 85 | ? 85 to < 86 | ? 86 |
| 2018 | PDP | < 80 | ? 80 to < 81 | ? 81 to < 83 | ? 83 to < 87 | ? 87 |
| 2017 | MA-PD | < 80 | ? 80 to < 82 | ? 82 to < 84 | ? 84 to < 86 | ? 86 |
| 2017 | PDP | < 79 | ? 79 to < 80 | ? 80 to < 83 | ? 83 to < 86 | ? 86 |
| 2016 | MA-PD | < 80 | ? 80 to < 82 | ? 82 to < 84 | ? 84 to < 86 | ? 86 |
| 2016 | PDP | < 80 | ? 80 to < 81 | ? 81 to < 82 | ? 82 to < 86 | ? 86 |
| 2015 | MA-PD | < 82% | ? 82% to < 83% | ? 83% to < 84% | ? 84% to < 87% | ? 87% |
| 2015 | PDP | < 80% | ? 80% to < 81% | * | ? 81% to < 86% | ? 86% |
Lowest-scoring contracts, 2022
| Contract | Parent | Members | Score | Stars | Δ | Shortfall to 4★ | Pctile |
|---|---|---|---|---|---|---|---|
| H5991 EmblemHealth | EmblemHealth, Inc. | 2,285 | 77 | 1 | 0 | 10 | 0% |
| S8182 Amerigroup | Elevance Health, Inc. | — | 79 | 1 | — | 5 | 0% |
| H4213 Arkansas Blue Medicare | USAble Mutual Insurance Company | 2,258 | 79 | 1 | 0 | 8 | 0% |
| H8432 Anthem Blue Cross and Blue Shield HP | Elevance Health, Inc. | 43,447 | 80 | 1 | 0 | 7 | 0% |
| H3890 Johns Hopkins Advantage MD | Johns Hopkins Healthcare LLC | 6,787 | 80 | 1 | 0 | 7 | 0% |
| H5439 Wellcare | Centene Corporation | 19,153 | 80 | 1 | 0 | 7 | 0% |
| H6154 Medica | Medica Holding Company | 1,801 | 81 | 1 | 0 | 6 | 1% |
| H2450 Medica | Medica Holding Company | 117,203 | 81 | 1 | 0 | 6 | 1% |
| H1353 Wellcare | Centene Corporation | — | 81 | 1 | — | 6 | 1% |
| H3154 Horizon Blue Cross Blue Shield of New Jersey | Horizon Healthcare Services, Inc. | — | 81 | 1 | 0 | 6 | 1% |
| H3206 Presbyterian Insurance Company, Inc. | Presbyterian Healthcare Services | — | 81 | 1 | 0 | 6 | 1% |
| H1894 Wellpoint | Elevance Health, Inc. | 2,322 | 81 | 1 | 0 | 6 | 1% |
| S7126 Mutual of Omaha Rx | Mutual of Omaha Insurance Company | — | 80 | 2 | — | 4 | 2% |
| S2874 Humana | Humana Inc. | — | 80 | 2 | 0 | 4 | 2% |
| S7694 Elixir Insurance | Rite Aid Corporation | — | 80 | 2 | 0 | 4 | 2% |
| H9302 Premera Blue Cross Medicare Advantage | Premera | — | 82 | 1 | 0 | 5 | 2% |
| H2056 Aetna Medicare | CVS Health Corporation | 8,275 | 82 | 1 | — | 5 | 2% |
| H0724 Wellcare | Centene Corporation | 0 | 82 | 1 | 0 | 5 | 2% |
| H5793 Aetna Medicare | CVS Health Corporation | 63,182 | 82 | 1 | 0 | 5 | 2% |
| H3748 Aetna Medicare | CVS Health Corporation | 4,321 | 82 | 1 | — | 5 | 2% |
| H0107 Blue Cross and Blue Shield of Montana | Health Care Service Corporation | 102,207 | 82 | 1 | 0 | 5 | 2% |
| H3288 Aetna Medicare | CVS Health Corporation | 68,564 | 82 | 1 | — | 5 | 2% |
| H8764 Aspire Health | Montage Health | 8,379 | 82 | 1 | 0 | 5 | 2% |
| H1666 Blue Cross and Blue Shield of NM, TX | Health Care Service Corporation | 15,741 | 82 | 1 | 0 | 5 | 2% |
| H0351 Wellcare | Centene Corporation | 23,066 | 82 | 1 | 0 | 5 | 2% |
History
| Star year | Code | Name | Measured | Weight | Source |
|---|---|---|---|---|---|
| 2027 | D05 | Rating of Drug Plan | 03/2026 – 06/2026 | 2 | CAHPS |
| 2026 | D05 | Rating of Drug Plan | 03/2025 – 05/2025 | 2 | CAHPS |
| 2025 | D05 | Rating of Drug Plan | 03/2024 – 06/2024 | 4 | CAHPS |
| 2024 | D05 | Rating of Drug Plan | 03/2023 – 06/2023 | 4 | CAHPS |
| 2023 | D05 | Rating of Drug Plan | 03/2022 – 06/2022 | 4 | CAHPS |
| 2022 | D05 | Rating of Drug Plan | 03/2021 – 05/2021 | 2 | CAHPS |
| 2021 | D07 | Rating of Drug Plan | 03/2019 – 05/2019 | 2 | CAHPS |
| 2020 | D07 | Rating of Drug Plan | 03/2019 – 05/2019 | 1.5 | CAHPS |
| 2019 | D07 | Rating of Drug Plan | 03/2018 – 06/2018 | 1.5 | CAHPS |
| 2018 | D08 | Rating of Drug Plan | 03/2017 – 06/2017 | 1.5 | CAHPS |
| 2017 | D08 | Rating of Drug Plan | 02/2016 – 08/2016 | 1.5 | CAHPS |
| 2016 | D08 | Rating of Drug Plan | 02/15/2015 - 05/31/2015 | 1.5 | CAHPS |
| 2015 | D06 | Rating of Drug Plan | 02/15/2014 - 05/31/2014 | 1.5 | CAHPS |